

**REMS Document
Initial Approval 07/2014**

NDA 205858 and NDA 206545

ZYDELIG™ (idelalisib) tablets

Drug Class: Phosphoinositide-3 Kinase-Delta Inhibitor

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Phone: (800) 445-3235

Risk Evaluation and Mitigation Strategy (REMS)

I. GOAL(S):

The goal of the Zydelig REMS is to mitigate the risks of fatal and /or serious hepatotoxicity, fatal/or serious and severe diarrhea or colitis, fatal and serious pneumonitis, and fatal and serious intestinal perforation associated with Zydelig treatment by informing prescribers of the risks of

- fatal and/or serious hepatotoxicity
- fatal and/or serious and severe diarrhea or colitis
- fatal and serious pneumonitis
- fatal and serious intestinal perforation

II. REMS ELEMENTS

A. Communication Plan

Gilead Sciences, Inc. (Gilead) will implement the following communication plan for Healthcare Providers who are likely to prescribe Zydelig. The communication plan will consist of the following:

1. **REMS Letter** - A *REMS Letter to Healthcare Providers* will be distributed within 30 days after the REMS approval date. The letter will be distributed electronically to oncologists and hematologists who are likely to prescribe Zydelig. If a targeted Healthcare Provider's email address is not available, or if an email is undeliverable, the provider will receive the letter through the mail. The *REMS Letter to Healthcare Providers* will inform Healthcare Providers of the risks of fatal and/or serious hepatotoxicity, fatal and/or serious and severe diarrhea or colitis, fatal and serious

pneumonitis, and fatal and serious intestinal perforation associated with Zydelig treatment. The letter will be accompanied by the Prescribing Information (with Medication Guide attached) and the *Zydelig REMS Fact Sheet*. The *REMS Letter to Healthcare Providers* will be available from the *Zydelig REMS Website* at the time of distribution and will remain on the website for the duration of the REMS.

2. **REMS Letter for Professional Societies** - A *REMS Letter for Professional Societies* will be distributed electronically within 30 days after the REMS approval date. If a targeted Professional Societies' email address is not available, or if an email is undeliverable, the letter will be sent through the mail. The *REMS Letter for Professional Societies* will inform the leadership of the professional societies described below of the risks of fatal and/or serious hepatotoxicity, fatal and/or serious and severe diarrhea or colitis, fatal and serious pneumonitis, and fatal and serious intestinal perforation associated with Zydelig treatment. Gilead will request the leadership of the professional societies to distribute this risk information to their memberships.

The *REMS Letter for Professional Societies* will be distributed to the following organizations:

- American Society of Clinical Oncology (ASCO)
- American Society of Hematology (ASH)
- Oncology Nursing Society (ONS)
- National Comprehensive Cancer Network (NCCN)
- Hematology Oncology Pharmacy Association (HOPA)
- American Pharmacists Association (APhA)
- American Society of Health-System Pharmacists (ASHP)

3. **REMS Fact Sheet** – A *Zydelig REMS Fact Sheet* will be distributed to Healthcare Providers. The *Zydelig REMS Fact Sheet* will be included in the mailings of the *REMS Letter to Healthcare Providers* and the *REMS Letter for Professional Societies* and will be available on the *Zydelig REMS website*. Hard copies of the *Zydelig REMS Fact Sheet* will also be distributed by Gilead's sales representatives and medical field-based personnel to Healthcare Providers during follow-up details/visits with Healthcare Providers for the first 12 months after the approval of the Zydelig REMS.

4. **Journal Information Piece** - Gilead will publish in the following professional journals an information piece that includes the risks of fatal and/or serious hepatotoxicity, fatal and/or serious and severe diarrhea or colitis, fatal and serious pneumonitis and fatal and serious intestinal perforation associated with Zydelig treatment.

- Journal of Clinical Oncology
- Blood
- New England Journal of Medicine
- Hematology Oncology Today
- Oncology & Hematology Review

- Leukemia and Lymphoma

The information piece will be published quarterly in each publication for one year following the REMS approval.

- 5. Scientific Meetings** – The *Zydelig REMS Fact Sheet* and the Prescribing Information will be prominently displayed at scientific meetings where Gilead has a presence (e.g., booth) through the end of December 2015 following the REMS approval.
- 6. Zydelig REMS website** –The website will contain information on the Zydelig REMS and will provide access to all the REMS materials, and the Prescribing Information and Medication Guide. The website will be available for the duration of the REMS.
- 7. Zydelig Patient Safety Information Card** - A patient safety information card will highlight the risks of Zydelig and include information on the management of these risks. Gilead’s sales representatives or medical field based personnel will distribute the patient safety information cards to prescribers. The patient safety information card will also be available on the Zydelig REMS website.

The following are part of the REMS and are appended.

- The *REMS Letter to Healthcare Providers*
- The *REMS Letter for Professional Societies*
- The *REMS Fact Sheet*
- The Journal Information Piece
- The *Zydelig REMS Website* (Landing Page)
- Zydelig Patient Safety Information Card

B. Timetable for Submission of Assessments

Gilead will submit REMS assessments to the FDA 18 months, 3 years, and 7 years after approval of the initial REMS. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment so that it will be received by the FDA on or before the due date.